A well-designed REMS program protects more than compliance. It helps safeguard launch timelines, maintain patient access, and reduce operational risk. Envision brings together deep REMS expertise and commercialization insight to help biopharmaceutical companies navigate complexity with confidence.
Protect launch timelines. Maximize patient access. Reduce operational and compliance risk.
REMS requirements can emerge unexpectedly, particularly for therapies with complex safety profiles.
Early assessment gives you time to prepare for potential FDA requirements and protect launch timelines. It also lets you build the right infrastructure from the start, one that fits how providers already work and coordinates with your other product and patient support programs, so meeting safety obligations is straightforward for the providers responsible for them.
Therapies that may warrant REMS assessment include:
Examples are illustrative only. REMS requirements are determined by the FDA based on a product’s specific benefit-risk profile and safety considerations.
30+ REMS programs supported
Supporting branded, generic, specialty pharmaceutical, and biotechnology products across a broad range of therapeutic areas.
50+ years of combined REMS leadership experience
Deep expertise spanning REMS strategy, design, implementation, assessment, compliance audits, and ongoing program management.
Expertise across the full safety lifecycle
Experience supporting REMS, Risk Management Plans (RMPs), Controlled Access Programs (CAPs), patient registries, and broader post-marketing safety initiatives for new products, products approaching loss of exclusivity, and generics and biosimilars.
Supporting products from development through post-launch
Helping teams anticipate requirements early, protect launch timelines, maintain patient access, and reduce operational and compliance risk throughout the product lifecycle.
Understand the likelihood of a REMS requirement early and prepare for potential regulatory, operational, and commercialization implications before approval.
Develop tailored REMS strategies for new and existing products that balance safety requirements with patient access, provider adoption, and regulatory success.
Build and deploy REMS programs, including regulatory documentation, technology solutions, REMS websites, contact centers, training materials, and operational infrastructure.
Manage ongoing program operations and commitments, including assessments, knowledge surveys, stakeholder audits, noncompliance management, and inspection readiness activities to ensure long-term program success.
Leverage scalable technology and governance processes that support compliance, transparency, audit readiness, and efficient program management.
Extend risk management beyond REMS through RMPs, CAPs, patient registries, and broader post-marketing safety support.
Explore our latest thinking and how we partner with clients to tackle complex challenges and advance the future of healthcare.
REMS decisions affect far more than regulatory compliance. They can influence approval timelines, launch readiness, patient access, healthcare provider adoption, operational burden, and long-term product success.
As part of Envision Pharma Group, our specialists work alongside experts in regulatory, patient engagement, market access, medical affairs, commercialization, and technology. This connected approach helps ensure your REMS and safety strategy supports broader business objectives while maintaining the highest standards of patient safety and regulatory compliance.
Whether you’re evaluating REMS risk, preparing for launch, implementing a new program, or managing ongoing compliance and operations, our specialists can help you navigate complexity with confidence.
Contact us to learn how our REMS and post-marketing safety experts can support your product, patients, and commercialization strategy.
